Lack of CD8⁺ T Cell Effector Differentiation during Priming Mediates Checkpoint Blockade Resistance in Non–Small Cell Lung Cancer

Researchers used an orthotopic non–small cell lung cancer mouse model to study immune checkpoint blockade-refractory CD8+ T cell responses.